 | Up a level |
Kienle, Dirk L.; Dietrich, Daniel; Ribi, Karin; Wicki, Andreas; Quagliata, Luca; Winterhalder, Ralph C.; Koeberle, Dieter; Horber, Daniel; Bastian, Sara; Kueng, Marc; Saletti, Piercarlo; Helbling, Daniel; Baertschi, Daniela; Lugli, Alessandro; Bernhard, Jürg; Andrieu, Christiane; von Moos, Roger (2019). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of geriatric oncology, 10(2), pp. 304-310. Elsevier 10.1016/j.jgo.2018.11.011
Koeberle, Dieter; Betticher, Daniel; Von Moos, Roger; Dietrich, Daniel; Brauchli, Peter; Baertschi, Daniela; Matter-Walstra, Klazien; Winterhalder, Ralph; Borner, Markus; Anchisi, Sandro; Moosmann, Peter; Kollár, Attila; Saletti, Piercarlo; Roth, Arnaud; Frueh, Martin; Kueng, Marc; Popescu, Razvan; Schacher, Sabina; Hess, Viviane and Herrmann, Richard (2013). O-0028 Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial. Annals of oncology, 24(Suppl 4), iv22-iv22. Oxford University Press 10.1093/annonc/mdt201.28
